Global Retinal Vein Occlusion Treatment Industry is poised to grow at 5.9% CAGR by 2033, attributing the surge to escalating incidences of CRVO and BRVO | FMI

Retinal Vein Occlusion Treatment Industry

The global retinal vein occlusion treatment industry is likely to register a CAGR of 5.9% to reach US$ 4.7 billion during forecast from 2023 to 2033. According to Future Market Insights, a valuation of US$ 2.3 billion is expected for the industry by the end of 2023. Retinal vein occlusion is among the most pervasive retinal vascular ailments in older individuals, and mainly affects people over the age of 65. Age is a significant potential risk for retinal vein occlusion. As the elderly population goes up, it is presumed that the incidence of retinal vein occlusion will increase as well.

The global retinal vein occlusion treatment industry refers to the pharmaceuticals and medical devices used to manage and treat retinal vein occlusion, a condition where a vein in the retina becomes blocked or partially blocked. RVO can lead to vision loss or impairment if left untreated.

Discover Our Expert Analysis with Our Sample Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-16599

There are two main types of retinal vein occlusion: central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). Treatment options for RVO aim to reduce the swelling and improve blood flow in the affected retina, thus preserving vision and preventing further damage.

The retinal vein occlusion treatment market is driven by advancements in technology, increasing prevalence of retinal diseases, and the aging population. Pharmaceutical companies and medical device manufacturers play a significant role in developing innovative treatments and devices for RVO.

Key Takeaways from the Market Study:

• Global retinal vein occlusion treatment market to reach a valuation of US$ 4.7 billion in 2033
• East Asia retinal vein occlusion market is expected to expand at a CAGR of 6.5%.
• From 2018 to 2022, sales increased significantly at a CAGR of 5%.
• The random-effects gathered likelihood of RVO in Europeans over the age of 55 was 0.7%, according to a 2018 Pubmed report.
• The total number of affected people in the EU is expected to nearly double, from 900,000 in 2018 to 1.1 million in 2050.

“Players in the retinal vein occlusion treatment domain are increasing their capacity to produce corticosteroid drugs, which can help combat the inflammatory factors that cause edema. Healthcare professionals, on the other hand, are becoming increasingly skilled in focal laser therapy,” says FMI’s analyst.

Feel Free To Reach Out To Our Analyst For Any Queries You Might Have! https://www.futuremarketinsights.com/ask-question/rep-gb-16599

Market Competition:

Key players in the retinal vein occlusion treatment market are AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Kodiak Sciences Inc., Chugai Pharmaceuticals, and Novartis AG among others.

• Novartis affirmed highly supportive for the initial interpretable Phase III findings of a clinical study investigating the effectiveness and protection of Beovu in December 2020. Beovu by Novartis placed Regeneron’s anti-VEGF Eylea, one of the renowned treatments for diabetic macular edema, in direct competition.
• Roche is presently performing Phase III trials to examine the effectiveness and security of Faricimab in sick people with macular edema secondary to BRVO and CRVO, with the drug anticipated to be approved by 2023 based on the findings.

Key Segments Profiled in the Retinal Vein Occlusion Treatment Industry Survey:

By Drug Class:

• Ranibizumab
• Dexamethasone
• Aflibercept
• Bevacizumab

By Type:

• Central Retinal Vein Occlusion
• Branch Retinal Vein Occlusion

By Diagnosis:

• Optical Coherence Tomography
• Fundoscopic Examination
• Fluorescein Angiography

By End User:

• Hospitals
• Research and Academics
• Specialty Clinics

By Region:

• North America
• Europe
• East Asia
• South Asia
• Oceania
• Latin America
• Middle East and Africa (MEA)

Act Now to Explore In-Depth Market Analysis: Get Exclusive Purchase Now to Access! https://www.futuremarketinsights.com/checkout/16599

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube